Cited 0 times in
Programmed death-ligand 1 expression in carcinoma of unknown primary
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구자승 | - |
dc.contributor.author | 김혜민 | - |
dc.date.accessioned | 2024-06-14T02:45:00Z | - |
dc.date.available | 2024-06-14T02:45:00Z | - |
dc.date.issued | 2024-06 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199720 | - |
dc.description.abstract | We examined the expression of programmed death-ligand 1 (PD-L1) in carcinoma of unknown primary (CUP) and its potential implications. Tissue microarrays were constructed for 72 CUP cases (histologic subtypes: 22 adenocarcinoma, 15 poorly differentiated carcinoma, 19 squamous cell carcinoma, and 14 undifferentiated carcinoma; clinical subtype: favorable type 17 [23.6%], unfavorable type 55 [76.4%]), with immunohistochemical staining performed for PD-L1 (22C3, SP142, SP263, and 28 − 8), CK7, and CK20 to determine the association between staining results and clinicopathological parameters. In CUP, the PD-L1 positivity rate was 5.6–48.6% (tumor cells [TC] or tumor proportion score [TPS]: 5.6–36.1%, immune cell score [IC]: 8.3–48.6%, combined positive score [CPS]: 16.7%) using different cutoff values for 22C3 (TPS ≥ 1%, CPS ≥ 10), SP142 (TC ≥ 50%, IC ≥ 10%), SP263, and 28 − 8 (TC and IC ≥ 1%). PD-L1 SP142 TC and PD-L1 SP263 IC showed the lowest (5.6%) and highest (48.6%) positivity rates, respectively. The PD-L1 positivity rate did not significantly differ based on the histologic subtype, clinical subtype, or CK7/CK20 across clones. Considering TC κ ≥ 1%, TC κ ≥ 50%, IC κ ≥ 1%, and IC κ ≥ 10%, the PD-L1 positivity rate was TC = 4.2–36.1% and IC = 9.7–48.6%; the overall agreement between antibodies ranged from 69.4 to 93.1%, showing fair or better agreement (κ ≥ 0.21). In CUP, PD-L1 positivity varied depending on antibodies and scoring systems, with no difference observed according to histologic or clinical subtypes. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | B7-H1 Antigen* / metabolism | - |
dc.subject.MESH | Biomarkers, Tumor* / metabolism | - |
dc.subject.MESH | Carcinoma, Squamous Cell / metabolism | - |
dc.subject.MESH | Carcinoma, Squamous Cell / pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasms, Unknown Primary* / metabolism | - |
dc.subject.MESH | Neoplasms, Unknown Primary* / pathology | - |
dc.subject.MESH | Tissue Array Analysis | - |
dc.title | Programmed death-ligand 1 expression in carcinoma of unknown primary | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학교실) | - |
dc.contributor.googleauthor | Hye Min Kim | - |
dc.contributor.googleauthor | Ja Seung Koo | - |
dc.identifier.doi | 10.1186/s12885-024-12437-w | - |
dc.contributor.localId | A00198 | - |
dc.contributor.localId | A04553 | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.identifier.pmid | 38844907 | - |
dc.subject.keyword | Carcinoma | - |
dc.subject.keyword | PD-L1 | - |
dc.subject.keyword | Primary known | - |
dc.contributor.alternativeName | Koo, Ja Seung | - |
dc.contributor.affiliatedAuthor | 구자승 | - |
dc.contributor.affiliatedAuthor | 김혜민 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 689 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.24(1) : 689, 2024-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.